ReviewGlycoconjugate journal2021
Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression.
Review in Glycoconjugate journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06438900 (Fighting Western-diet Derived AGEs to Mitigate Muscle Wasting in Sarcobesity), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fighting Western-diet Derived AGEs to Mitigate Muscle Wasting in Sarcobesity:Observational Study on the Relationship Between AGE Levels and Sarcobesity in an Adult Population Affected by Obesity and Type 2 Diabetes Mellitus
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances.International journal of molecular sciences · 2026Review
- Advanced glycation end products (AGEs) and their role in diabetes mellitus and related complications: mechanisms and therapeutic insights.Glycoconjugate journal · 2025Review
- Acrylamide and Advanced Glycation End Products in Frying Food: Formation, Effects, and Harmfulness.Foods (Basel, Switzerland) · 2025Review
- NOX4 as an emerging prognostic and immunological biomarker across pan-cancer analyses.Scientific reports · 2025Article
- Association of acrylamide dietary intake with glycation and oxidative status biomarkers and intakes of advanced glycation end-products or alpha-dicarbonyls.Scientific reports · 2025Article
- Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury.Toxins · 2025Article
- Methylglyoxal Formation-Metabolic Routes and Consequences.Antioxidants (Basel, Switzerland) · 2025Review
- L-Theanine Extends the Lifespan ofFoods (Basel, Switzerland) · 2025Article
- Colorectal Cancer Cell-Derived Extracellular Vesicles Promote Angiogenesis Through JAK/STAT3/VEGFA Signaling.Biology · 2024Article
- Interplay of Glucose Metabolism and Hippo Pathway in Chondrocytes: Pathophysiology and Therapeutic Targets.Bioengineering (Basel, Switzerland) · 2024Review
- Review
- The role of dysregulated metabolism and associated genes in gastric cancer initiation and development.Translational cancer research · 2024Review
- Review
- Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.Apoptosis : an international journal on programmed cell death · 2024Article
- Glycosylation Modulates the Structure and Functions of Collagen: A Review.Molecules (Basel, Switzerland) · 2024Review
- Identification of potential shared gene signatures between gastric cancer and type 2 diabetes: a data-driven analysis.Frontiers in medicine · 2024Article
- Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms.Frontiers in endocrinology · 2024Review
- Nε-(1-Carboxymethyl)-L-lysine/RAGE Signaling Drives Metastasis and Cancer Stemness through ERK/NFκB axis in Osteosarcoma.International journal of biological sciences · 2024Article
- Article
- Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer.World journal of diabetes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex disease with a 5-10% hereditary base, but nutrition, lifestyle, and the environment we are exposed to influence 90-95% of cancers. Due to rapid westernization, the diet we consume is rich in advanced glycation end products (AGEs). AGEs are the heterogeneous group of compounds formed by non-enzymatic reactions between reducing sugars and amino groups of proteins, lipids, and nucleic acids. Its implication is confirmed in many chronic conditions such as diabetes, renal, cardiovascular diseases, and aging however its role in cancer development has been understudied. Cancer cells are continuously exposed to AGEs due to their increased production, owing to its high metabolic rate and aerobic glycolysis. AGEs accumulation led to glycative stress which in turn stimulates oxidative stress and inflammation, through its receptor known as receptor for advanced glycation end products (RAGE). RAGE mediates crosstalk between the tumour cells and its microenvironment components to induce hypoxia, mitochondrial dysfunction, endoplasmic reticulum stress, autophagy, epigenetic modification, and cancer stemness. This emphasizes AGEs as an essential driving factor in different aspects of cancer development, but the exact molecular mechanism has to be explored. Thus, this review gives an insight into the pathological role of AGEs at the bio-molecular level in the tumourigenesis and progression of cancer in terms of the tumour microenvironment, invasion, and metastasis. Further, the compiled clinical data relating to the AGE-RAGE axis associated with different cancers and its potential inhibitors have been discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.